Cargando…

High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19

BACKGROUND: Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) differ in the severity of disease. We hypothesized that characteristics of SARS-CoV-2–specific immunity correlate with disease severity. METHODS: In this study, SARS-CoV-2–specific T cells and antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales: Schub, David, Klemis, Verena, Schneitler, Sophie, Mihm, Janine, Lepper, Philipp M., Wilkens, Heinrike, Bals, Robert, Eichler, Hermann, Gärtner, Barbara C., Becker, Sören L., Sester, Urban, Sester, Martina, Schmidt, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605520/
https://www.ncbi.nlm.nih.gov/pubmed/32937615
http://dx.doi.org/10.1172/jci.insight.142167
_version_ 1783604317956079616
author Schub, David
Klemis, Verena
Schneitler, Sophie
Mihm, Janine
Lepper, Philipp M.
Wilkens, Heinrike
Bals, Robert
Eichler, Hermann
Gärtner, Barbara C.
Becker, Sören L.
Sester, Urban
Sester, Martina
Schmidt, Tina
author_facet Schub, David
Klemis, Verena
Schneitler, Sophie
Mihm, Janine
Lepper, Philipp M.
Wilkens, Heinrike
Bals, Robert
Eichler, Hermann
Gärtner, Barbara C.
Becker, Sören L.
Sester, Urban
Sester, Martina
Schmidt, Tina
author_sort Schub, David
collection PubMed
description BACKGROUND: Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) differ in the severity of disease. We hypothesized that characteristics of SARS-CoV-2–specific immunity correlate with disease severity. METHODS: In this study, SARS-CoV-2–specific T cells and antibodies were characterized in uninfected controls and patients with different coronavirus disease 2019 (COVID-19) disease severity. SARS-CoV-2–specific T cells were flow cytometrically quantified after stimulation with SARS-CoV-2 peptide pools and analyzed for expression of cytokines (IFN-γ, IL-2, and TNF-α) and markers for activation, proliferation, and functional anergy. SARS-CoV-2–specific IgG and IgA antibodies were quantified using ELISA. Moreover, global characteristics of lymphocyte subpopulations were compared between patient groups and uninfected controls. RESULTS: Despite severe lymphopenia affecting all major lymphocyte subpopulations, patients with severe disease mounted significantly higher levels of SARS-CoV-2–specific T cells as compared with convalescent individuals. SARS-CoV-2–specific CD4(+) T cells dominated over CD8(+) T cells and closely correlated with the number of plasmablasts and SARS-CoV-2–specific IgA and IgG levels. Unlike in convalescent patients, SARS-CoV-2–specific T cells in patients with severe disease showed marked alterations in phenotypical and functional properties, which also extended to CD4(+) and CD8(+) T cells in general. CONCLUSION: Given the strong induction of specific immunity to control viral replication in patients with severe disease, the functionally altered characteristics may result from the need for contraction of specific and general immunity to counteract excessive immunopathology in the lung. FUNDING: The study was supported by institutional funds to MS and in part by grants of Saarland University, the State of Saarland, and the Rolf M. Schwiete Stiftung.
format Online
Article
Text
id pubmed-7605520
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society for Clinical Investigation
record_format MEDLINE/PubMed
spelling pubmed-76055202020-11-04 High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19 Schub, David Klemis, Verena Schneitler, Sophie Mihm, Janine Lepper, Philipp M. Wilkens, Heinrike Bals, Robert Eichler, Hermann Gärtner, Barbara C. Becker, Sören L. Sester, Urban Sester, Martina Schmidt, Tina JCI Insight Clinical Medicine BACKGROUND: Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) differ in the severity of disease. We hypothesized that characteristics of SARS-CoV-2–specific immunity correlate with disease severity. METHODS: In this study, SARS-CoV-2–specific T cells and antibodies were characterized in uninfected controls and patients with different coronavirus disease 2019 (COVID-19) disease severity. SARS-CoV-2–specific T cells were flow cytometrically quantified after stimulation with SARS-CoV-2 peptide pools and analyzed for expression of cytokines (IFN-γ, IL-2, and TNF-α) and markers for activation, proliferation, and functional anergy. SARS-CoV-2–specific IgG and IgA antibodies were quantified using ELISA. Moreover, global characteristics of lymphocyte subpopulations were compared between patient groups and uninfected controls. RESULTS: Despite severe lymphopenia affecting all major lymphocyte subpopulations, patients with severe disease mounted significantly higher levels of SARS-CoV-2–specific T cells as compared with convalescent individuals. SARS-CoV-2–specific CD4(+) T cells dominated over CD8(+) T cells and closely correlated with the number of plasmablasts and SARS-CoV-2–specific IgA and IgG levels. Unlike in convalescent patients, SARS-CoV-2–specific T cells in patients with severe disease showed marked alterations in phenotypical and functional properties, which also extended to CD4(+) and CD8(+) T cells in general. CONCLUSION: Given the strong induction of specific immunity to control viral replication in patients with severe disease, the functionally altered characteristics may result from the need for contraction of specific and general immunity to counteract excessive immunopathology in the lung. FUNDING: The study was supported by institutional funds to MS and in part by grants of Saarland University, the State of Saarland, and the Rolf M. Schwiete Stiftung. American Society for Clinical Investigation 2020-10-15 /pmc/articles/PMC7605520/ /pubmed/32937615 http://dx.doi.org/10.1172/jci.insight.142167 Text en © 2020 Schub et al. http://creativecommons.org/licenses/by/4.0/ This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Medicine
Schub, David
Klemis, Verena
Schneitler, Sophie
Mihm, Janine
Lepper, Philipp M.
Wilkens, Heinrike
Bals, Robert
Eichler, Hermann
Gärtner, Barbara C.
Becker, Sören L.
Sester, Urban
Sester, Martina
Schmidt, Tina
High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19
title High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19
title_full High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19
title_fullStr High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19
title_full_unstemmed High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19
title_short High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19
title_sort high levels of sars-cov-2–specific t cells with restricted functionality in severe courses of covid-19
topic Clinical Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605520/
https://www.ncbi.nlm.nih.gov/pubmed/32937615
http://dx.doi.org/10.1172/jci.insight.142167
work_keys_str_mv AT schubdavid highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19
AT klemisverena highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19
AT schneitlersophie highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19
AT mihmjanine highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19
AT lepperphilippm highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19
AT wilkensheinrike highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19
AT balsrobert highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19
AT eichlerhermann highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19
AT gartnerbarbarac highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19
AT beckersorenl highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19
AT sesterurban highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19
AT sestermartina highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19
AT schmidttina highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19